Table of Contents
PHILADELPHIA — Lannett Co. has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive U.S. distributor for metoprolol succinate extended-release tablets, a cardiovascular medication.
Financial terms weren’t disclosed. Lannett said late Wednesday that its metoprolol succinate product — available in dosages of 25 mg, 50 mg, 100 mg and 200mg — is an authorized generic version of Toprol-XL ER tablets from Aralez.
“Metoprolol succinate is a widely prescribed medication and will be an important addition to our cardiovascular product offering,” stated Arthur Bedrosian, chief executive officer of Lannett. “We expect to launch the product, under the Lannett label, in the near future.”
A beta-blocker, metoprolol succinate ER tablets are used to treat angina, heart failure and high blood pressure, helping to prevent strokes, heart attacks, and kidney problems.
U.S. sales of metoprolol succinate ER tablets (25 mg, 50 mg, 100 mg and 200 mg) at average wholesale price totaled approximately $690 million for the 12 months through September, according to IQVIA (formerly QuintilesIMS) data reported by Lannett.